TY - JOUR
T1 - Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients
AU - Teh, Benjamin W.
AU - Mikulska, Malgorzata
AU - Averbuch, Dina
AU - de la Camara, Rafael
AU - Hirsch, Hans H.
AU - Akova, Murat
AU - Ostrosky-Zeichner, Luis
AU - Baddley, John W.
AU - Tan, Ban Hock
AU - Mularoni, Alessandra
AU - Subramanian, Aruna K.
AU - La Hoz, Ricardo M.
AU - Marinelli, Tina
AU - Boan, Peter
AU - Aguado, Jose Maria
AU - Grossi, Paolo A.
AU - Maertens, Johan
AU - Mueller, Nicolas J.
AU - Slavin, Monica A.
N1 - Publisher Copyright:
© 2024 Elsevier Ltd
PY - 2024/1
Y1 - 2024/1
N2 - Patients can be immunocompromised from a diverse range of disease and treatment factors, including malignancies, autoimmune disorders and their treatments, and organ and stem-cell transplantation. Infections are a leading cause of morbidity and mortality in immunocompromised patients, and the disease treatment landscape is continually evolving. Despite being a critical but preventable and curable adverse event, the reporting of infection events in randomised trials lacks sufficient detail while inconsistency of categorisation and definition of infections in observational and registry studies limits comparability and future pooling of data. A core reporting dataset consisting of category, site, severity, organism, and endpoints was developed as a minimum standard for reporting of infection events in immunocompromised patients across study types. Further additional information is recommended depending on study type. The standardised reporting of infectious events and attributable complications in immunocompromised patients will improve diagnostic, treatment, and prevention approaches and facilitate future research in this patient group.
AB - Patients can be immunocompromised from a diverse range of disease and treatment factors, including malignancies, autoimmune disorders and their treatments, and organ and stem-cell transplantation. Infections are a leading cause of morbidity and mortality in immunocompromised patients, and the disease treatment landscape is continually evolving. Despite being a critical but preventable and curable adverse event, the reporting of infection events in randomised trials lacks sufficient detail while inconsistency of categorisation and definition of infections in observational and registry studies limits comparability and future pooling of data. A core reporting dataset consisting of category, site, severity, organism, and endpoints was developed as a minimum standard for reporting of infection events in immunocompromised patients across study types. Further additional information is recommended depending on study type. The standardised reporting of infectious events and attributable complications in immunocompromised patients will improve diagnostic, treatment, and prevention approaches and facilitate future research in this patient group.
UR - http://www.scopus.com/inward/record.url?scp=85170692207&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85170692207&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(23)00377-8
DO - 10.1016/S1473-3099(23)00377-8
M3 - Review article
C2 - 37683684
AN - SCOPUS:85170692207
SN - 1473-3099
VL - 24
SP - e59-e68
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 1
ER -